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Aims: This paper presents an e-survey of current clinical practice of use of intra-operative diuretics
during renal transplantation in the United Kingdom and a study to compare outcome of renal transplants
carried out with or without intra-operative diuretics in our centre.
Methods: An e-mail questionnaire to renal transplant surgeons exploring their practice of renal trans-
plantation with or without intra-operative diuretics, the type of a diuretic/s if used and the relevant
doses. An observational study comparing the outcome of renal transplant recipients, group no-diuretics
(GND, n ¼ 80) carried out from 2004 to 2008 versus group diuretics (GD n ¼ 69) renal transplant
recipients who received intra-operative diuretics over a one year period is presented. Outcome measures
were incidence of delayed graft function and a comparison of graft survival in both groups.
Results: Forty surgeons answered from 18 transplant centres with a response rate of 67%. 13 surgeons do
not use diuretics. Mannitol is used by 10/40, Furosemide 6/40 and 11 surgeons use a combination of both.
In comparative study there was no signiﬁcant overall difference in one year graft survival of GD versus
GND (N ¼ 65/69, 94% and 75/80, 94% respectively, p ¼ 0.08) and the incidence of delayed graft function
was also comparable (16/69, 23% and 21/80, 26% respectively, p ¼ 0.07). The donor characteristics in both
groups were comparable.
Conclusion: The study showed variation in clinical practice on the use of intra-operative diuretics in renal
transplantation and it did not demonstrate that the use of diuretics can improve renal graft survival.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The term Delayed graft function (DGF) is controversial and most
commonly used for lack of acceptable renal function requiring
dialysis in one week after transplantation.1 DGF does not occur after
all renal transplantations; there is a wide variation in reporting
(5e93%) depending on the source of the graft,2,3 but most centres
report a DGF rate of 20e40%.4 However the term DGF remains vague
and there are a number of criterion and deﬁnitions described for
DGF. Factors associated with an increased occurrence of DGF can be
categorised in to three areas, i.e. donor, recipient and transplant
procedure.5 Donor factors include: increased age, hypertension (>10
years), creatinine clearance <80 mL/min, vascular sclerosis, weight,
female gender, and atraumatic death. Recipient factors are pre-
sensitization, ethnicity, pre-transplant levels of proinﬂammatory
cytokines, pre-transplant anuria, pre-transplant mean arterial
pressure (<100 mmHg), and American Society of Anesthesiologists
physical status category IV (a patient with an incapacitating systemic
disease that is a constant threat to life). Transplant procedural factorsurio).
ciates Ltd. Published by Elsevier Ltcomprise cold ischemia time, warm ischemia time, anastomotic
time, and selection of preservation solution.5
One important co-existing or contributory factor to DGF which
can delay the primary function of the transplanted kidney is acute
tubular necrosis. The incidence of post operative acute tubular
necrosis (ATN) after cadaveric kidney transplantation has been
reported in the literature to vary from 30 to 60%.6e9 There is
controversy about the inﬂuence of ATN on the ultimate fate of the
graft.9 In a study of 354 transplantations performed in Nijmegen,
incidence of ATN of 42% was reported with a signiﬁcant negative
inﬂuence on graft survival. Apart from its possible adverse effect on
graft survival it is important to prevent ATN because it hampers the
diagnosis of early rejection, increases the necessity of diagnostic
procedures (radionuclide scans, echography, and transplant
biopsies), and introduces dialysis-associated morbidity. Traditional
strategy to prevent ATN is the use of adequate hydration in combi-
nationwith diuretics during renal implantation. The haemodynamic
condition of the donor prior to nephrectomy and the length of initial
warm ischemia time have been considered major determinants in
the development of ATN after surgery.10 However, a number of
recent studies have indicated that the haemodynamic parameters of
the recipient during the transplantation procedure are of even
greater importance. Luciani et al.11 and Carlier et al.12 were able tod. All rights reserved.
Table 1
A comparison of donor and recipient characteristics in diuretics and no-diuretics
groups.




Recipient age (Years) 40  14 42  16^^
Donor age (Years) 42  16 43  16^^
Donor retrieval creatinine (umol/L) 81  33 86  31^^^
Cold ischemia (hours)
Cadaveric donor 17  3 17 þ 5^
Living donor 2½  1 2  1^^
Warm ischemia (Minutes)
Cadaveric donor 30  7 33  7^^
Living donor 31  9 31  6^
HLA mismatch 2 (1e4) 2 (1e4)^
Median and IQR
umol/Lmicromole per litre, HLA human leukocyte antigen, IQR interquartile range, P
value 0.08^, 0.07^^, 0.06^^^ ManneWhitney U Test and student t test.
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by maximal hydration of the recipient during the operative proce-
dure. However the evidence to support the use of diuretics in order
to prevent ATN is scarce and anecdotal.13 This paper presents
a sequential study on the use of intra-operative diuretics in renal
transplantation. The study describes a survey of the use of diuretics
in various transplant centres in the United Kingdom. It is followed by
an analysis of the outcome of renal transplants carried out without
any intra-operative diuretics in our centre and their comparisonwith
a cohort of patients who received diuretics during surgery.
2. Methods
An e-mail questionnaire was circulated to renal transplant surgeons in various
transplant centres in the United Kingdom. It was a 4 item questionnaire to explore
the personal practice of renal transplant surgeons about the use of intra-operative
diuretics during kidney implantation. The questions asked were aimed to explore
the use of any intra-operative diuretics/combination of diuretics or no diuretics
during renal transplantation and their doses used.
Delayed graft function was deﬁned as requirement of dialysis within one week
after transplantation for reasons other than hyperkalaemia or ﬂuid overload. A
retrospective analysis of the outcome of those patients (N¼ 80) who were not given
any intra-operative diuretics during renal transplantation in a ﬁve year period
(2004e2008) in our centre was carried out (Group non- diuretics, GND). The
outcome of GND was then compared with those 69 transplants who were given
diuretics (Group diuretics, GD), carried out over a period of one year in our centre,
March 2008 to February 2009. The choice of diuretics or none was individual
surgeon’s policy and was consistent in all cases performed by the same surgeon.
All renal transplantations were carried out under the supervision of consultant
surgeons by using retroperitonal approach. All transplants carried out from 2006
onwards received same immunosuppression regimens including a combination of
Prednisolone, Tacrolimus (therapeutic range 5e8) and Mycophenolate (2 gram
daily). Prednisolonewas startedwith a dose of 20milligram (mg) and then gradually
reduced to 5 mg over a period of 3 months. All recipients of kidney transplant from
a heart beating deceased donor or live donor also received Basiliximab 20 mg before
implantation and 4th post operative day. However transplant recipients from non
heart beating donors received Daclizumab instead. The transplants carried out
before 2006 received a Cyclosporine and Azathioprine based immunosuppression
regimen. The intra-operative diuretics regimen used was variable according to
surgeon’s choice. One surgeon used no diuretics in any of his patients (GND), one
surgeon used Furosemide 80 mg and another surgeon 250 mg and one used
Mannitol 20 g in GD before revascularization of the kidney. The recipients were kept
well hydrated during and after the transplants especially in immediate post oper-
ative period. All recipients were given intravenous ﬂuids to maintain a central
venous pressure (CVP) between 10 and 12mmHg (millimeter of Mercury) andwhen
a stable CVPwas achieved, intravenous ﬂuid equal to 50mL plus previous hour urine
output was given. The most common intravenous ﬂuid used was a combination of
normal saline and 5% dextrose water. A baseline biopsy was part of transplant
protocol in all cases, followed by a biopsy on day 7 only in the cases of delayed graft
function. An ultrasound scan on day 1was also part of protocol to ensure satisfactory
perfusion and to exclude hydronephrosis.
The hospital database system and case notes were used to obtain the patient
demographics and other relevant data. The basic demographics included age,
gender, HLA mismatch status, cold ischemia time, warm ischemia time and pre-
operative renal function of the donor. Outcome measures were incidence of
delayed graft function and a comparison of graft and patient survival in both groups.
SPSS 15.0 was used for statistical analysis and KaplaneMeier curve to measure graft
and patient survival. ManneWhitney U test was used to compare medians and
student t- test to compare means between different groups. A p value of less than
0.05 was considered as signiﬁcant.
3. Results
3.1. The survey
Forty surgeons answered the questionnaire from 18 transplant
centres with a response rate of 67%. 13 surgeons did not use any
intra-operative diuretics for renal transplantation. Mannitol was
used by 10/40, Furosemode 6/40 and 11 surgeons used a combina-
tion of both including one using Dopamine in addition. The dose
range of Furosemide was 20e250 mg and Mannitol 1G to 20 g per
kg body weight. One surgeon excluded diuretics for living donor
transplants and another gave Furosemide 40 mg as compared to
a combination of Mannitol and Furosemide for deceased donorstransplants. Out of 18 centres, only in 7 centres all surgeons had
a consistent policy of using same diuretic regimen.3.2. The comparison of GD versus GND
The GD consisted of 45/69 deceased donor and 24/69 living
donor transplants as compared to 58/80 deceased donors and 17/80
living donors in GND. The donor and recipient characteristics in
both groups were comparable as given in Table 1. There was no
signiﬁcant overall difference in one year graft survival of GD versus
GND (N¼ 65/69, 94% and 75/80, 94% respectively, p¼ 0.08) and the
incidence of delayed graft function was also comparable (16/69,
23% and 21/80, 26% respectively, p¼ 0.07). The incidence of delayed
graft function showed a better trend in living donor transplants in
GND but rest of the outcomemeasures were comparable as given in
Table 2. The patients with DGF under went renal transplant biopsy
which revealed acute rejection in 11, acute tubular necrosis 9 and
CNI toxicity in 1 patient in GND. Whereas the biopsies in GD with
DGF revealed acute rejection in 4 and ATN in 9 recipients of
cadaveric donor grafts and 2 acute rejections and 1 indeterminate
biopsy in living donor transplants (Table 2). KaplaneMeier survival
curve measured 5 year patient survival 94% (Conﬁdence Interval
95%, 93-96) in GND and there was no patient loss in 12 months
follow-up of GD.4. Discussion
It has been well established that adequate hydration and stable
blood pressure have beneﬁcial effect on the transplanted kidney
and the incidence of DGF and ATN can be reduced by these
measures.14 However there is very little data which could ﬁrmly
support that any clinical beneﬁt could be achieved by the use of
diuretics such as Furosemide or Mannitol intra-operatively. That is
probably the reason for a signiﬁcant variation in clinical practice of
use of intra-operative diuretics by different surgeons as shown by
the survey presented in this study. Out of 18 centres, only in 7
centres all surgeons had a consistent policy of using same diuretic
regimen. The dose of diuretics was variable from centre to centre
and there was a variation in practice on the choice and dose of
diuretics by the same surgeons for different patients depending
upon the donor type. Moreover 13 out of 40 surgeons did not use
any diuretics. This clearly showed a lack of any consistent and
replicable policy and the choice of diuretics or no diuretics is purely
dependent on surgeon’s preference and is not based on any robust
clinical evidence. It would be important to mention that Tiggler
et al. in a study published in 1985 showed that there was some
added beneﬁt in reducing ATN after combining moderate hydration
Table 2





Deceased donors N ¼ 45 N ¼ 63
One year graft survival 42, (93) 58, (92)^
Delayed graft function 13, (29) 21 (33)^^
Five year graft survival NA 58 (92)
Living donors N ¼ 24 N ¼ 17
One year graft survival 23, (96) 17 (100)^^
Delayed graft function 3, (13) 0^^^
Five year graft survival NA 17 (100)
All transplantsa N ¼ 69 N ¼ 80
One year graft survival 65, (94) 75 (94)^
Delayed graft function 16, (23) 21 (26)^^
ATN 9 (13%) 9 (11%)^^^
a All transplants deceased and living donors, NA not applicable (12 months follow
up only for GD), N Number, ATN acute tubular necrosis on transplant biopsy, p value
0.08^, 0.07^^, 0.06^^^, KaplaneMeier curve and student t test.
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ﬂuid regimens with or without Mannitol.13 However it was not
clariﬁed if moderate hydration alonewould give similar ATN rate or
not when compared to moderate hydration and Mannitol regimen.
Our study has clearly shown that diuretics use not only varies from
centre to centre but also from surgeon to surgeon. Similarly in
current literature there is no consensus as to the practice of intra-
operative ﬂuid replacement (crystalloid or colloid), how much
they should be given, use of Mannitol, Furosemide and Dopamine.
The practice varies from centre to centre, individual surgeons
within the same centre and even anaesthetists within the same
centre.14e17 All patients in our study received moderate hydration
with a uniform ﬂuid replacement protocol to keep CVP 10e12 mm
Hg. The goal is to keep CVP above 10 mm Hg so that the intravas-
cular compartment, which often is contracted prior to renal
transplant, is ﬁlled up particularly just before the release of clamps.
This is done in order to minimize the chances of ATN. The earlier
the occurrence of this episode the greater will be the likelihood of
graft dysfunction.9,12e14
The donor risk factors in both GD and GND were comparable
(Table 1). The incidence of DGFwas numerically better in GD (29%) as
compared to GND (33%) in case of deceased donor transplants and
inferior (GD 13% versus GND 0) in case of living donor transplants.
Nevertheless there was no signiﬁcant difference noted in DGF, ATN
and one year graft survival in each group (Table 2). All living donor
recipients (n¼ 17) inGNDhad a functioning graft at 5 year follow-up.
This ﬁnding was limited by the fact that we had not as yet reached to
a stage of 5 year follow-up ﬁgure for GND but no difference in one
year graft survivalwasnoted ineither group (94%). The studyﬁndings
show no signiﬁcant difference in terms of reduction in ATN or DGF
and improvement in graft survival with or without the use of
diuretics as long as patients are moderately hydrated.
Transplant recipients vary widely in terms of their respective
pathological state. They might have Type II Diabetes, advanced
cardiomyopathy, vasculitis, sickle cell disease and morbid obesity.
Hence intra-operative ﬂuidmanagement and diuretic use should be
case speciﬁc. To stress upon the above mentioned observation one
must consider that there is a signiﬁcantly high incidence of
myocardial dysfunction in patients with renal failure and particu-
larly those on dialysis.18 Observational studies indicate that
congestive heart failure (CHF) is 12e36 times more prevalent
in dialysis patients as compared with the general population.19e21
It has been demonstrated by Wali et al that kidney trans-
plantation can be performed safely in ESRD (end stage renal failure)
patients with decreased LVEF (left ventricular ejection fraction)
(<40%), advanced heart failure, and without inducible ischemia.Kidney transplantation resulted in an increase in LVEF in more than
86%of patients. Even amajority of patientswith pre-transplant LVEF
<20% had normalized LVEF in the post-transplant period.18 It is
important to emphasize that in these high risk patients, intra-
operative ﬂuids/diuretics are given cautiously and the whole prac-
tice is tailored according to the patient’s cardiovascular status. This
can be measured and calibrated during surgery not only by CVP but
also by non invasive methods of cardiac output monitoring. The
practice of giving diuretics or no diuretics, the volume and the kind
of ﬂuid (crystalloid or colloid or both), Dopamine infusion and its
dose depends on speciﬁc indicators of a particular patient.
It is a small size study but at least the ﬁndings highlight the need
for a well designed randomized controlled trial to clarify the
rationale of use of intra-operative diuretics in renal transplantation.
The unnecessary use of diuretics can have potential detrimental
effects on the renal transplant recipient and their use may have
some cost implications but there is no ﬁrm evidence to support this
and vice versa and that is why more studies are required for the
assessment of clinical risks versus beneﬁts.22,23
5. Conclusion
The study has shown that there is a huge variation in clinical
practice of the use of intra-operative diuretics in renal trans-
plantation in the United Kingdom. The role of diuretics in reducing
the incidence of acute tubular necrosis and delayed graft function is
equivocal. Moreover the study did not show any relation between
the use of diuretics and improvement in renal graft survival. Each
patient needs an individualized intra and post operative regimen
according to the end stage kidney disease and the comorbidities.
The results of the study emphasize the need for well designed
larger studies to clarify the role of the use of intra-operative
diuretics during renal transplant surgery.
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